About GLG Institute Events

GLG Institute events are designed to create a candid environment for executives to share challenges and insights in a trusted and confidential space. These are off-the-record and invite-only events.

Ascend: The Essential Leadership Experience

Deepen leadership competencies required to succeed in the C-suite beyond business strategy and domain expertise. In this four-part leadership series, GLG Institute Advisors with deep operating experience will share their wisdom on navigating the biggest challenges facing senior executives today.


Get multiple perspectives to act with confidence on complex decisions by connecting in a small interactive group setting with trusted Advisors and peers. Roundtables are offered either virtually or in-person with dinner.

Annual In-Person Summit

Foster connections and inspire action by convening with Advisors and peer participants across organizations for one to two days of highly interactive, off-the-record discussions about top industry and leadership issues.

Ascend: The Essential Leadership Experience

Past Event
Functional to C-Suite Leadership with Sheri McCoy and Padma Thiruvengadam

Occurred February 29, 2024

Read Speaker Bios

Past Event
Making Tough Talent Decisions with Christi Shaw and Fabrice Enderlin

Occurred April 16, 2024

Read Speaker Bios

Communication and Executive Presence with Matt Kohut and Barbara Ryan

Wednesday, September 18th at 10am ET

Read Speaker Bios

Mental Health and the Psychology of Leadership with Denice Torres

Fall 2024

Read Speaker Bio

Speaker Biographies

Sheri McCoy

Sheri McCoy is former Chief Executive Officer and director of Avon Products, Inc. Prior to Avon, Ms. McCoy had a distinguished 30-year career at Johnson & Johnson serving as Vice Chairman of the Executive Committee, responsible for the Pharmaceutical and Consumer business segments that represented more than 60 percent of the company’s revenues.

Ms. McCoy joined Johnson & Johnson as a scientist in research and development and subsequently managed businesses in every major product sector, including consumer, prescription medicines and medical devices where she held roles including Worldwide Chairman, Pharmaceuticals Group and Worldwide Chairman Surgical Care Group. Ms. McCoy has experience in mergers and acquisitions and management of complex global structures.

Sheri serves on the public boards of AstraZeneca PLC, a global, science-led biopharmaceutical business; Stryker, a Medical Device company; Kimberly-Clark, a consumer company and Novocure, an Oncology company. Sheri also works as an Industrial Advisor for EQT Partners and is Chairman of Certara, a private company focused on biosimulation in drug development and regulatory sciences. Additionally, Sheri is a member of Catalyst, a global non-profit that helps build workplaces that work for women, and Stonehill College. Ms. McCoy holds a Bachelor of Science degree in textile chemistry from the University of Massachusetts, Dartmouth, a master’s degree in chemical engineering from Princeton University, and an MBA from Rutgers University. She holds four U.S. patents and she has been on Fortune magazine’s “50 Most Powerful Women in Business” list.

Padma Thiruvengadam Headshot

Padma Thiruvengadam

Padma Thiruvengadam served as CHRO at Takeda Pharmaceutical Company – a $30BN+ global Fortune 500 company with over 50K+ employees in 85 countries – where she led the business to achieve a Global Top Employer certification for 3 years in a row, while orchestrating the integration of the largest acquisition in the pharmaceutical industry. She transformed the entire global organization to deliver on the new strategy and refreshed corporate philosophy and purpose. She also architected a new HR operating model, people vision, and people platform and programs. She recreated board and executive compensation programs to meet shareholder expectations; and leading award-winning DEI initiatives in several countries around the world. Previously as Chief People Officer for The Lego Company – recognized as the planet’s most powerful brand, Padma embraced the Board’s charge to create a strategic pivot that would allow the company to address new market dynamics and revitalize the revenue stream. She drove organizational capability building, onboarded new executives, and led a company-wide shift to workforce agility. Prior to joining Lego, Padma provided strong leadership as CHRO and CVP, Strategic Initiatives and Operational Excellence for Integra Life Sciences where she partnered with the Board of Directors on CEO assessment and succession plan. Working closely with the new CEO, she built the transformation strategy and delivered on it to positively impacted corporate growth. Padma previously held General Management responsibilities as VP, Asia Pacific and Canada for Pfizer’s oncology business unit. As VP, Business Integration, she led all integration activities globally for Pfizer Oncology – acquisition of Wyeth. In her first role with Pfizer as VP, Human Resources, Padma advised senior business leaders on overall HR strategies while partnering with the President and GM of Pfizer Oncology to create and operationalize the new business unit. Earlier in her career, Padma served as SVP, Human Resources Executive in 2 different business groups at Bank of America where she led business and people initiatives to expand the company’s global footprint. Padma completed her Master’s degree coursework at the University of Madras and holds a Bachelor’s degree from Osmania University, both in India.

Speaker Biographies

Christi Shaw

Christi Shaw is a life sciences leader and advocate for patients with more than 30 years of pharmaceutical industry experience across a broad range of therapeutic areas. Christi is driven by values, integrity, and a deep commitment to accelerating innovation and enabling access to offer unprecedented hope to patients battling difficult-to-treat diseases.

Most recently, Christi served as Chief Executive Officer of Kite, a Gilead Company, a member on the executive committee and the board of directors for the Biotechnology Innovation Organization (BIO) and held senior executive positions at Lilly, Novartis Corp. and Johnson & Johnson. Christi holds a bachelor’s degree in business administration from Iowa State University and an MBA from the University of Wisconsin. Christi is very active in sustainable farming and resides with her husband and son in Santa Monica, CA.

Fabrice Enderlin

Fabrice Enderlin is the former Executive Vice President Corporate Human Resources of the UCB Group, and currently leads an independent consultancy, DiscernYard. He is currently setting up family talent strategies (governance, succession, people development) for family own businesses and supporting CEO’s, CHRO’s and C suite members. He has extensive experience within the Biopharma world initially with Ciba-Geigy where he joined a production plant in 1991, before supporting the Novartis merger in 1997 as Vice President HR Pharma France. He joined GSK in 2000 leading as Vice President HR France broad change management activities during the merger of the two Anglo-saxon companies. In 2003, he embraced an international career supporting the fast growth of the vaccines division of GSK as Vice President HR within GSK Biologicals, based in Belgium. At UCB, Fabrice took on additional responsibilities besides the initial HR activities, including the operational excellence team, the Global Communication department as well as the Corporate Social Responsibility (CSR) area.

Speaker Biographies

Matt Kohut

Matthew Kohut, managing partner of KNP Communications, has prepared CEOs, entrepreneurs, ambassadors, scientists, and best-selling authors for events ranging from television appearances to TED talks. Prominent clients include Fortune 500 firms and 3 of the world’s top 10 business schools. Matt has held appointments at George Washington University and Bennington College. He is the author of Speaking Out: The New Rules of Business Leadership Communication, and co-author of two other books. His writing has appeared in publications ranging from Harvard Business Review to Newsweek.

Barbara Ryan

Barbara Ryan founded Barbara Ryan Advisors, a capital markets and communications advisory firm for the life sciences industry, in 2012 following a 30+ year career on Wall Street as a sell-side research analyst and Managing Director covering the U.S. large-cap pharmaceutical industry, distributors and PBMs. Ms. Ryan has deep experience in equity and debt financings, M&A, valuation, SEC reporting, financial analysis, corporate and communications strategy across the life sciences industry and has raised well over $1.5 billion in equity and convertible debt offerings. Ms. Ryan has been involved in several of the pharmaceutical industry’s largest M&A transactions: Shire’s defense against a hostile takeover attempt by Abbvie, Shire’s takeover of Baxalta, Allergan’s defense against Valeant and Perrigo’s defense again Mylan. Ms. Ryan served as an executive team member and on the disclosure committee of Radius Health from January 2014 to December 2017 and played a critical role in Radius’ IPO and subsequent follow-on offerings which raised over $1 billion. Previously, Ms. Ryan was a Managing Director at Deutsche Bank/Alex Brown and head of the company’s Pharmaceutical Research Team for 19 years. She began her research career covering the pharmaceutical industry at Bear Stearns in 1982. Ms. Ryan also covered drug wholesalers and PBMs, and was the lead-analyst on many high-profile IPOs, including Express Scripts, PSSI, Henry Schein, and Flamel Technologies. Ms. Ryan currently serves as a director on the boards of Indivior PLC, MiNK Therapeutics as Audit Chair, INVO Biosciences, OcuTerra Therapeutics, and Safecor. Barbara also serves on board of The Red Door Community NYC, a non-profit organization for cancer support, and is on the Editorial Advisory Board of Pharmaceutical Executive Magazine, where she authors a monthly Finance Column, and is a member of the Editorial Advisory Board of the Prix Galien Foundation and a faculty member at the GLG Institute and The Biopharma Hub. Barbara is the founder Fabulous Pharma Females, a non-profit whose mission is to advance women in the biopharma industry. Ms. Ryan has also led the development of women leadership programs at several biotech companies.

Speaker Biography

Denice Torres is CEO of The Ignited Company change management firm and Founder of The Mentoring Place, a non-profit organization dedicated to helping women advance in their careers. She has over 30 years of P&L, commercial, and strategy experience in pharmaceuticals, medical devices, and consumer healthcare. She served as president for several multi-billion-dollar Johnson & Johnson companies including Janssen Pharmaceuticals (CNS), and J&J Consumer Healthcare. Denice was also chief strategy and transformation officer for the medical device sector. Denice is credited for successfully leading and transforming the Tylenol company through an unprecedented time period marked by product recalls, manufacturing challenges, and a consent decree. She was named the Healthcare Businesswoman of the Year in 2015.

Prior to joining J&J, Denice had a highly successful, 14-year career at Lilly where she served in leadership roles of increasing responsibility, including executive director for women health and head of global marketing for a multi-billion CNS portfolio.

Denice has served on multiple boards and is currently a director of bluebird bio (BLUE), Karuna Therapeutics (KRTX) and Resilience. She holds an M.B.A. from the University of Michigan, a J.D. from Indiana University School of Law, and a B.S. in Psychology from Ball State. She is a member of the Michigan Bar Association.

Roundtables and Dinners

Past Event
Lessons in Leadership with Deborah Dunsire

Occurred March 19, 2024

Read Deborah’s Bio

Past Event
In-Person Roundtable and Dinner with Marc de Garidel
Zurich, Switzerland

Occurred April 25, 2024

Read Marc’s Bio

In-Person Roundtable and Dinner with Paul Sekhri
Cambridge, MA

Fall 2024

Read Paul’s Bio

Into the Boardroom with Irene Chang-Britt

Wednesday, October 2, 2024
10:00am ET

Read Irene’s Bio

In-Person Roundtable and Dinner
Europe TBA

Fall 2024

Speaker Bio Coming Soon

Lessons in Leadership with Deborah Dunsire

Deborah Dunsire M.D. was President and CEO of H. Lundbeck A/S, a global bio-pharma company, present in 56 countries and helping over 8 million patients every day. The company focuses on restoring brain health so every person can be their best. The Copehagen headquartered company discovers, develops and commercializes therapies in mental health as well as neurological diseases. She served there from 2018-2023.

Prior to her tenure at Lundbeck, Deborah was CEO and President at XTuit Pharmaceuticals, a start up focused on novel drug delivery encapsulation technology to treat tumors and fibrotic diseases. From 2013-2016, she was President and CEO at FORUM Pharmaceuticals a company that focused in therapies for Alzheimer’s disease and other dementias as well as therapies to improve cognition in Schizophrenia.

She served as president and CEO of Millennium Pharmaceuticals from 2005 to 2013, during which time Takeda Pharmaceuticals of Japan acquired it for $8.8 billion. Following the acquisition, Deborah became the first woman to be appointed to the board of Takeda Pharmaceuticals in Japan.

Prior to her role at Millenium, Deborah spent 17 years at Sandoz and Novartis and led the Novartis Oncology business in North America, launching a number of transformational cancer therapies.

Deborah currently serves on the boards of Ultragenyx Pharmaceuticals and Syros Pharmaceuticals. She has also served on the board of Alexion Pharmaceuticals until its sale to Astra Zenenca. Until its sale to Actavis in March of 2015, Deborah was a long standing board member of Allergan Pharmaceuticals and has also served for many years as a board member of the Biotechnology Innovation Organization.

Currently Deborah serves as a trustee of the Museum of Science (Boston). She is on the board of trustees for Northeastern University.

Deborah was born in Zimbabwe and completed her medical training in South Africa.


Marc De Garidel – CEO and Interim Chairman, Abivax Former CEO, Ipsen SA

Marc de Garidel is a successful Pharma/biotech entrepreneur. He was recently appointed CEO & Interim Chairman of Abivax to be effective in May 2023. Prior to that, Marc led 2 multibillion exits with CinCor Pharma sold to AstraZeneca in February 2023 for $1.8B in total considerations & Corvidia Therapeutics to Novo Nordisk in August 2020 for $2.1B in total considerations.

From 2010 to 2016, he served as Chairman and CEO of Ipsen SA, where he led a significant transformation of Ipsen, effecting a three-fold increase in market capitalization, launching the blockbuster oncology drug Somatuline Depot (lanreotide) in the U.S., and completing the ex-U.S. commercialization deal with Exelixis on CABOMETYX (cabozantinib).

Prior to his experience at Ipsen SA, Marc spent 15 years with the multinational biopharmaceutical company Amgen. Based primarily in Europe, Marc helped Amgen establish and build a significant business in nephrology and oncology, achieving leadership positions for several portfolio products.

He began his career with Eli Lilly and Company where he worked in the United States, France and Germany. In Europe, Marc has played a prominent role in not-for-profit organizations such as the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). He is currently the president of G5 Sante’. Marc served on the Board of Directors for Vifor Pharmaceuticals AG as a member and in 2018 as Vice Chair. He remains Chair of the Board of Directors for Ipsen SA.

Marc holds a Master’s degree in civil engineering from École Spéciale des Travaux Publics in Paris and an executive MBA from Harvard Business School.

Paul Sekhri – President and CEO, vTv Therapeutics, Inc.

Paul Sekhri has over 35 years of experience in the Life Science Industry. His experience encompasses senior management in large corporate pharmaceutical and biotechnology companies, as well as private equity and venture capital.

Mr. Sekhri is President and Chief Executive Officer of vTv Therapeutics, Inc. Most recently he served as President and CEO of eGenesis, Inc. from 2019-2022 where he remains a Board Member and Senior Advisor to the Chairman. Prior to joining eGenesis, he was President and CEO of Lycera Corp. from 2015-2019. Prior to this, he served as Senior Vice President, Integrated Care for Sanofi from 2014-2015. Previously, he served as Chief Strategy Officer and Group Executive Vice President, Global Business Development for Teva Pharmaceutical Industries, Ltd.

Prior to joining Teva, he spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004-2009, Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc.

Previously, Mr. Sekhri spent five years at Novartis as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG.

Mr. Sekhri has been a Director on more than 35 private, public company, and nonprofit Boards and is currently a member of the Board of Directors of Axcella Therapeutics, eGenesis, Inc., Ipsen, S.A., Longboard Pharmaceuticals, Spring Discovery and Veeva Systems Inc. Mr. Sekhri is also the Chairman of the Board of Compugen Ltd. and was, until recently, the Chairman of the Board of Pharming N.V. Additionally, he is on the Board of Directors of The Metropolitan Opera, The English Concert in America and was a member of the Board of Trustees of Carnegie Hall. Most recently he was nominated as Chairman of the Board of Trustees of Young Concert Artists, Inc

Board Workshop 101 Roundtable

Irene Chang Britt
is an experienced and forward-thinking independent board director, currently serving on the boards of global coffee & donut chain Dunkin Brands Group Inc., menswear leader Tailored Brands Inc. and next generation nutrition company TerraVia Inc. ​Irene is a National Association of Corporate Directors (NACD) Board Leadership Fellow and a frequent speaker on corporate governance best practices. Irene is a highly accomplished former Fortune 500 C-Suite executive with a long track record of transforming businesses to achieve industry leading growth. From 2012 through 2015, she was President, Pepperidge Farm and SVP, Global Baking and Snacking for the Campbell Soup Company, capping a decade of executive service at the company that also included tenure as Global Chief Strategy Officer, President of North America Foodservice and VP & General Manager, Sauces and Beverages.

Before joining Campbell Soup in 2005, Irene held a number of leadership positions within Kraft Foods / Nabisco in both the U.S. and Canada. Before that, she spent more than a decade at Kimberly-Clark, where she held key assignments in marketing, sales and R&D leadership. In addition to Dunkin Brands, Tailored Brands and TerraVia, Irene previously served on the board of energy company Sunoco, Inc., where she was a member of the audit committee, and worked on Sunoco’s strategic restructuring and ultimate 2012 sale to Energy Transfer Partners—delivering a 20% premium for shareholders. ​

Irene has been honored with a number of recognitions for her business and community accomplishments, including a Leadership Education for Asian Pacifics (LEAP) Award in 2014.

London In Person Roundtable

Speaker information for this event is coming soon. Check back here later for updates or email Katherine at institute@glgroup.com.

Annual In-Person Summit

Leadership Summit
New York City

Thursday, October 17 and Friday, October 18

More Details

Leadership Summit

Information on the 2024 Summit available here.


Event RSVP

Enter your information and select the event you’re interested in attending, and our team will reach out shortly with event invitation details.